Gabapentin Tablet
Product Images NDC 70518-2912

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2912). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 800mg 70518 2912 01)

Gabapentin is a prescription medication that is repackaged by RemedyRepack Inc. The manufacturing is done by Ascend Labs, LLC in Montvale, NJ. The medication should be kept out of sight and reach of children. The direction for use is located in the package insert. The medication should be stored between 20-26°C (63-77°F) with permissible excursions of 15-30°C (59-86°F) [See USP]. The Lot number and the Source NDC are available. The expiration date is not available.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin is a prescription drug that is sold by Ascend Labs, LLC. This medication is repackaged by Remedy Repack Inc. The recommended storage temperature for this medication is between 20-26°C but can be stored between 15-30°C. The packaging insert should be consulted for instructions on use.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

The given text is a medical formula for calculating creatinine clearance (CLCr) in female patients. CLCr is equal to the product of the serum creatinine value (given in mg/dL) multiplied by 72, which is then divided by the patient's age multiplied by 0.85. The text provides no further context or explanation.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

The text provides information regarding a study of pain management where a four-week dose titration period was followed by a four-week fixed dose period. It shows the mean pain score of 10 and the use of placebo and Gabapentin at a dosage of 3600 mg/day. The rest of the text appears to be unclear and unusable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

This appears to be a chart or table showing the mean pain score for different treatment groups over a period of weeks, with the baseline score at the start of the study. The treatments being compared are a placebo, and two different doses of Gabapentin (1800 mg/day and 2400 mg/day). The text does not provide any additional information or context beyond this.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

The text is showing a graph labeled as "Figure 3" that displays the percentage of patients who experienced a reduction in pain score in controlled PHN studies. The graph includes percentages ranging from 0% to 100%. The study results are compared between three treatments: GBP 3600, GBP 1800, and PBO. Some of the percentages are labeled with a number corresponding to a specific study but the information is incomplete and unclear. There is a note at the bottom of the graph that states "#p<001<0,001" but it is unclear what it refers to.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.